Search
SPL23-2
go.drugbank.com/drugs/DB17866ExperimentalSPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]
TTX-MC138
go.drugbank.com/drugs/DB18628InvestigationalTTX-MC138 is an antisense oligonucleotide targeting miR-10b.[L48335] It is under investigation for the treatment of various metastatic cancers.
Dihydroxyacetone phosphate
go.drugbank.com/drugs/DB04326InvestigationalDihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is not an inhibitor of CYP1A2.[A39048]
Brazikumab
go.drugbank.com/drugs/DB16115InvestigationalBrazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Foralumab
go.drugbank.com/drugs/DB16170InvestigationalForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
ATX-F8-117
go.drugbank.com/drugs/DB17712ExperimentalATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]
BHV-5000
go.drugbank.com/drugs/DB17817ExperimentalBHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]
Biricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Carafiban
go.drugbank.com/drugs/DB19813ExperimentalCarafiban has a monoisotopic molecular weight of 465.2 Da.